Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

6.160 +0.010 (+0.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
From Kezar Life Science
Via Business Wire
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Appoints Courtney Wallace to its Board of Directors
From Kezar Life Sciences
Via Business Wire
Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present at the Jefferies London Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc.
From Oxford Finance LLC
Via Business Wire
Kezar Reports Third Quarter Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar to Host Virtual Investor and Analyst Day on November 15, 2021
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Announces Formation of Clinical Advisory Committee
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors
From Kezar Life Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.